Russian Convacell Covid-19 vaccine to be supplied to Central, Latin America - FMBA

ST. PETERSBURG. June 5 (Interfax) - Russia supplies flu vaccine to Central and Latin America and plans to supply the Convacell Covid-19 vaccine too, first deputy head of the Federal Medical-Biological Agency (FMBA) Tatyana Yakovleva said.

"We have laid good groundwork, especially in relations with Central America, Latin America and Caribbean countries. We not only share our practices and products but also supply our vaccines, including flu vaccines, and have been allowed to supply the Convacell [Covid-19] vaccine," Yakovleva said at the Drug Safety and Security in the BRICS Area session of the St. Petersburg International Economic Forum.

Convacell is going through the final stage of clinical trials, Yakovleva said. Less than 1% of over 265,000 people who took the vaccine have fallen ill, she said.

The vaccine's average efficacy is 85%, including 92% in patients older than 60, Yakovleva said.

FMBA has a vast experience of work with BRICS and other countries, including India and the United Arab Emirates, she said.